Discounted Cash Flow
Theravance Biopharma, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $48.6m | $-190.7m | $-101.1m | -391.9% | — |
| 2017 | $15.4m (-68.4%) | $-285.4m (-49.7%) | $-203.5m (-101.2%) | -1855.0% (-373.3%) | — |
| 2018 | $60.4m (292.4%) | $-215.5m (24.5%) | $-120.1m (41.0%) | -357.0% (80.8%) | — |
| 2019 | $73.4m (21.6%) | $-236.5m (-9.7%) | $-241.4m (-101.0%) | -322.1% (9.8%) | — |
| 2020 | $71.9m (-2.1%) | $-278.0m (-17.6%) | $-257.0m (-6.5%) | -386.9% (-20.1%) | — |
| 2021 | $55.3m (-23.0%) | $-199.4m (28.3%) | $-211.3m (17.8%) | -360.6% (6.8%) | $-2.87 |
| 2022 | $51.3m (-7.2%) | $872.1m (537.3%) | $-187.6m (11.2%) | 1698.5% (571.1%) | $11.85 (512.9%) |
| 2023 | $57.4m (11.8%) | $-55.2m (-106.3%) | $-29.5m (84.3%) | -96.1% (-105.7%) | $-1.00 (-108.4%) |
| 2024 | $64.4m (12.1%) | $-56.4m (-2.2%) | $-11.9m (59.8%) | -87.6% (8.8%) | $-1.15 (-15.0%) |
| 2025 | $107.5m (66.9%) | $105.9m (287.7%) | $238.5m (2109.8%) | 98.5% (212.4%) | $2.10 (282.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.